vzphotos/iStock Editorial via Getty Images
AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year.
The drugmaker disclosed in November that two Phase 2 studies of
